Pulmonary Hypertension: Molecular Mechanism, Diagnosis and Therapeutic Target
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Molecular Targeted Therapy".
Deadline for manuscript submissions: 10 June 2024 | Viewed by 875
Special Issue Editors
Interests: pulmonary hypertension associated with chronic lung diseases; developmental pathways in pathogenesis and reversal of chronic lung diseases with the focus on COPD/COPD-PH
Interests: pulmonary hypertension; chronic obstructive lung disease; chronic lung inflammation; inflammation-driven lung pathologies
Special Issue Information
Dear Colleagues,
Pulmonary hypertension (PH) is a life-threatening disease characterized by elevated blood pressure in the pulmonary circulation, resulting in compromised heart and lung function. While primary PH remains rare, the incidence of PH associated with lung diseases or left heart dysfunction is alarmingly high. Remodeling of the pulmonary vasculature is an important attribute of the disease that causes increased blood flow resistance and PH development. However, the pathologic mechanisms underlying pulmonary vascular remodeling remain elusive, and no specific treatment is available to induce reverse remodeling that would cure the disease for good.
This Special Issue delves into the molecular and cellular intricacies of PH development and explores the elusive goal of reversing vascular remodeling, aiming to find a definitive cure. Our Special Issue invites the authors to submit manuscripts focusing on translational studies that bridge the gap between laboratory findings and clinical applications, as well as advancements in diagnostic techniques for early and accurate PH identification. Furthermore, we explore the promising frontiers of novel therapeutic strategies that offer hope for effective management and improved outcomes. In addition to original data from preclinical and clinical studies, comprehensive and up-to-date review articles are also welcomed.
Dr. Stefan Hadzic
Dr. Marija Gredic
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pulmonary hypertension
- IPAH
- COPD-PH
- pulmonary vasculature
- vascular remodeling
- right ventricle
- cor pulmonale
- personalized medicine
- treatment
- reverse remodeling
